Showing results (1251-1260 of 1,427) with videos related to
Sort By:
Pageof 143
Journal of the National Cancer Institute|October 13, 2010
Advanced ovarian cancer: phase III randomized study of sequential cisplatin-topotecan and carboplatin-paclitaxel vs carboplatin-paclitaxelP Hoskins, I Vergote, A Cervantes, et al.International Journal of Radiation Oncology, Biology, Physics|October 18, 2016
Phase 1/2 Study of the Addition of Cisplatin to Adjuvant Chemotherapy With Image Guided High-Precision Radiation Therapy for Completely Resected Gastric CancerRebecca B Goody, Helen MacKay, Bethany Pitcher, et al.Gynecologic Oncology|April 16, 2021
The Prevent Ovarian Cancer Program (POCP): Identification of women at risk for ovarian cancer using complementary recruitment approachesAlicia A Tone, Jeanna M McCuaig, Nicole Ricker, et al.Heart Rhythm|July 25, 2024
High-frequency low-tidal volume ventilation improves procedural and long-term clinical outcomes in persistent atrial fibrillation ablation: Prospective multicenter registryJose Osorio, Daniela Hincapie, Allyson L Varley, et al.Current Oncology (Toronto, Ont.)|October 5, 2011
Progression-free survival in advanced ovarian cancer: a Canadian review and expert panel perspectiveA M Oza, V Castonguay, D Tsoref, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 5, 2021
Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD IK N Moore, A M Oza, N Colombo, et al.Investigational New Drugs|May 7, 2013
A phase I study of the oral gamma secretase inhibitor R04929097 in combination with gemcitabine in patients with advanced solid tumors (PHL-078/CTEP 8575)Suzanne Richter, Philippe L Bedard, Eric Xueyu Chen, et al.Intensive Care Medicine|June 22, 2021
Implementation of new ECMO centers during the COVID-19 pandemic: experience and results from the Middle East and IndiaAhmed A Rabie, Mohamed H Azzam, Abdulrahman A Al-Fares, et al.Journal of Medicinal Chemistry|May 4, 2012
Discovery of checkpoint kinase inhibitor (S)-5-(3-fluorophenyl)-N-(piperidin-3-yl)-3-ureidothiophene-2-carboxamide (AZD7762) by structure-based design and optimization of thiophenecarboxamide ureasVibha Oza, Susan Ashwell, Lynsie Almeida, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 16, 2023
Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor ProgressionStephanie Lheureux, Stephenie D Prokopec, Leslie E Oldfield, et al.Pageof 143